The Fibrolamellar Cancer Foundation (FCF) is accepting proposals to support innovative research leading to improved understanding and curative treatments for fibrolamellar carcinoma (FLC). FLC, also known as fibrolamellar hepatocellular carcinoma (FL-HCC), is an aggressive liver cancer that tends to strike teens and young adults.
Eligibility for Grant Application
Applicants must be employed by an institution engaged in health-related research. The research must focus specifically on FLC. Studies should be intended to advance knowledge relevant to the understanding, diagnosis, epidemiology, or treatment of FLC. Of particular interest are applications showing a clear path towards a novel therapy or clinical trials with the ultimate goal of achieving a cure for FLC. The Foundation will accept grant applications to support innovative and promising research projects towards the listed goals.
Collaboration and open sourcing are a requirement for FCF funding, as will be specified in any grant agreement. The Foundation believes that collaboration and engaging the best talent across institutions, together with early sharing of data and resources, can accelerate the path to a cure for rare cancers like FLC.
Grant Review Periods
Applications are reviewed three times annually, with application deadlines of February 1, June 1 and October 1. The Foundation is also open to time sensitive requests – particularly for truly innovative ideas – throughout the year, with agreement prior to submission.
For more information or to apply for a grant, click here to download the research grant application form. If you need additional information or would like to discuss a proposal concept before completing the application, please email us at email@example.com.